Sanofi expands Regeneron partnership with up to $8B deal

by@Reuters

Summary

Sanofi and Regeneron have expanded their partnership with a new agreement worth up to $8 billion to develop four new antibody drugs, including an upfront payment of $1 billion and additional milestone payments that could total $7 billion. This deal not only settles existing litigation between the partners but also addresses concerns regarding Dupixent, their successful eczema drug set to lose patent protection in 2031. The agreement marks a significant initial success for Sanofi's new CEO, Belen Garijo, who is focused on making timely strategic decisions. Under the terms, Regeneron will lead the research and development of these new drugs targeting type 2 inflammation pathways, while Sanofi will handle global sales, sharing both costs and profits equally.

Tokens

$SASY$REGN

Analysis

Sanofi: Sanofi is a global pharmaceutical company based in France with a focus on developing treatments in areas including immunology and inflammation. It maintains a longstanding collaboration with Regeneron on key products such as the eczema drug Dupixent. The expanded partnership announced today marks an early strategic success under its current leadership as the company advances new pipeline candidates. Regeneron: Regeneron is a US-based biotechnology company known for its work in antibody therapeutics and immunology. It partners with Sanofi on multiple programs, including the co-development and commercialization of Dupixent. Under the new agreement, Regeneron will lead research and development for the additional drugs while sharing profits equally with Sanofi. Paul Hudson: Paul Hudson previously served as chief executive of Sanofi. He had attempted earlier to broaden the company's collaboration with Regeneron but was unsuccessful in those efforts. Belen Garijo: Belen Garijo is the chief executive of Sanofi, having assumed the role in May and initiating a strategic review of the company's operations. She has emphasized faster decision-making to address investor priorities. The expanded Regeneron deal is viewed as an early win that demonstrates her proactive approach to key uncertainties facing the business. Michael Leuchten: Michael Leuchten is an analyst at Jefferies who covers the pharmaceutical industry. He commented positively on the expanded partnership, noting its role in addressing investor concerns and signaling progress under new leadership at Sanofi. Leadership Focus: The agreement is positioned as an early achievement for Sanofi's current CEO amid efforts to accelerate strategic decisions and mitigate risks around the Dupixent franchise. Development Structure: Regeneron will lead research and development for the new assets, while Sanofi will oversee global sales efforts, with both companies sharing costs and equally splitting future profits. Partnership Expansion: Sanofi and Regeneron are advancing four new antibody drugs that target the same type 2 inflammation pathways as their existing Dupixent product.

Categories

macro
View Original Tweet